AMENDMENTS TO THE CLAIMS

- 1. (Currently Amended) An isolated mammalian cell comprising
 - a. Aspergillus nidulans AlcR protein, which modulates transcription of operatorcontaining promoters in response to compounds being gaseous or liquid at cultivation temperature of said mammalian cell; and
 - a promoter operatively linked to P_{alcA} operator sites specific for binding Aspergillus nidulans AlcR protein obtained by amplifying said operator sites from an P_{alcA} containing vector with oligonucleotides OWW58 (SEQ ID NO:1) and OWW59 (SEQ ID NO:2).
- 2. (Previously Presented) The mammalian cell of claim I further comprising a nucleic acid encoding a desired protein functionally linked to said promoter operatively linked to the PaleA operator sites specific for binding Aspergillus nidulans AleR protein.
- 3. (Previously Presented) The mammalian cell of claim 1, wherein binding of the Aspergillus nidulans AlcR protein to operator-containing promoters is changed in response to compounds being gaseous at a cultivation temperature of said mammalian cell.
- 4. (Previously Presented) The mammalian cell of claim 1, wherein binding of the Aspergillus nidulans AlcR protein to operator-containing promoters is changed in response to compounds being liquid at a cultivation temperature of said mammalian cell.

5.-8. (Cancelled)

- (Previously Presented) A non-human mammal comprising at least one mammalian cell as claimed in claim 1.
- 10. (Withdrawn) A method for adjusting the expression level of a desired protein in a mammalian cell as claimed in claim 2, comprising culturing said mammalian cell and modulating gene expression by administration of a compound for which transcription of the

Serial No. 10/570,043 Attorney Docket No. 2006_0153A April 24, 2009

OP operator-containing promoter and the responsive transcription factor RTF are responsive.

- 11. (Withdrawn) The method of claim 10, wherein the protein is selected from the group consisting of SEAP, a fluorescent protein, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, insulin, erythropoietin, tissue plasminogen activator, DNAse, a monoclonal antibody, Factor VIII, Factor VII, HAS, IL-2, glucagons, EGF, GCSF, GMCSF, thrombopoietin, gp160, HbSAg, a protein encoded by a tumor suppressor gene, and a protein encoded by a gene interfering with absorption, distribution, metabolism and excretion of compounds contained in tobacco smoke.
- 12. (Withdrawn) The method of claim 10, wherein the compound for modulating gene expression is selected from the group consisting of ketones, aldehydes, haloalkanes, alcohols, esters, amines, and ethers.
- 13. (Withdrawn) The method of claim 10, wherein the compound for modulating gene expression is selected from the group consisting of ethanol, methylamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, n-hexylamine, benzylamine, 2-butanone, ethanol, n-propanol, n-butanol, 2-propanol, 2-butanol, 2-methylbutyraldehyde, acetaldehyde, propanal, acetone, 2-butanone, 2-pentanone, 3-pentanone, cyclohexanone, glycoaldehyde, glyoxal, glyoxylate, ethylene glycol, ethanolamine, ethyl acetate, ethyl ether, and dicyclopropylketone, and compounds that are metabolized in situ to said members of the group.
- 14. (Withdrawn) The method of claim 10, wherein the compound for modulating gene expression is selected from the group consisting of ethanol, methylamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, n-hexylamine, benzylamine, 2-butanone, ethanol, n-propanol, n-butanol, 2-propanol, 2-butanol, 2-methylbutyraldehyde, acetaldehyde, propanal, acetone, 2-butanone, 2-pentanone, 3-pentanone, cyclohexanone, glycoaldehyde, glyoxal, glyoxylate, ethylene glycol, ethanolamine, ethyl acetate, ethyl ether, and dicyclopropylketone.

Serial No. 10/570,043 Attorney Docket No. 2006_0153A April 24, 2009

- 15. (Withdrawn) The method of claim 10, wherein the RTF comprises amino acid sequences related to or derived from non-mammalian proteins.
- 16. (Withdrawn) The method of claim 10 wherein the RTF is the Aspergillus nidulans AlcR protein and the compound for modulating gene expression is acetaldehyde.
- 17. (Withdrawn) A method for adjusting the expression level of a gene in a mammalian cell as claimed in claim 1, comprising
 - a. functionally linking said gene to an OP-containing promoter,
 - transferring said OP-containing promoter functionally linked to said gene into said mammalian cell, and
 - c. inducing expression of said gene by activating said OP-containing promoter by administration of a compound for which the OP operator-specific responsive transcription factor RTF is responsive.
- 18. (Withdrawn) The method of claim 17, wherein the gene codes for a protein selected from the group consisting of SEAP, a fluorescent protein, human growth hormone, alphainterferon, beta-interferon, gamma-interferon, insulin, erythropoietin, tissue plasminogen activator, DNAse, a monoclonal antibody, Factor VIII, Factor VII, HAS, IL-2, glucagons, EGF, GCSF, GMCSF, thrombopoietin, gp160, and HbSAg.
- 19. (Withdrawn) The method of claim 17, wherein the gene is a tumor suppressor gene.
- 20. (Withdrawn) The method of claim 17, wherein the gene is a gene interfering with absorption, distribution, metabolism and excretion of compounds contained in tobacco smoke.
- 21. (Withdrawn) The method of claim 17, wherein the compound for which the OP operator-specific responsive transcription factor RTF is responsive is selected from the group consisting of ketones, aldehydes, haloalkanes, alcohols, esters, amines, and ethers.

Serial No. 10/570,043 Attorney Docket No. 2006_0153A April 24, 2009

- 22. (Withdrawn) The method of claim 17 wherein the compound for which the OP operator-specific responsive transcription factor RTF is responsive is selected from the group consisting of ethanol, methylamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, n-hexylamine, benzylamine, 2-butanone, ethanol, n-propanol, n-butanol, 2-propanol, 2-butanol, 2-methylbutyraldehyde, acetaldehyde, propanal, acetone, 2-butanone, 2-pentanone, 3-pentanone, cyclohexanone, glycoaldehyde, glyoxal, glyoxylate, ethylene glycol, ethanolamine, ethyl acetate, ethyl ether, and dicyclopropylketone, and compounds that are metabolized in situ to said members of the group.
- 23. (Withdrawn) The method of claim 17 wherein the compound for which the OP operator-specific responsive transcription factor RTF is responsive is selected from the group consisting of ethanol, methylamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, n-hexylamine, benzylamine, 2-butanone, ethanol, n-propanol, n-butanol, 2-propanol, 2-butanol, 2-methylbutyraldehyde, acetaldehyde, propanal, acetone, 2-butanone, 2-pentanone, 3-pentanone, cyclohexanone, glycoaldehyde, glyoxal, glyoxylate, ethylene glycol, ethanolamine, ethyl acetate, ethyl ether, and dicyclopropylketone.
- 24. (Withdrawn) The method of claim 17 wherein the OP-containing promoter is an AlcR-specific OP site, RTF is the Aspergillus nidulans AlcR protein, and the compound for which RTF is responsive is acetaldehyde.
- 25. (Withdrawn) An isolated nucleic acid useful for constructing a mammalian cell as claimed in claim 1, comprising an RTF-encoding nucleic acid functionally linked to a promoter useful for expression of the RTF in said mammalian cell.
- 26. (Withdrawn) The isolated nucleic acid of claim 25 comprising an OP sequence functionally linked to a promoter or a fragment thereof useful for RTF-dependent gene expression in said mammalian cell.

Serial No. 10/570,043 Attorney Docket No. 2006_0153A

April 24, 2009

27. (Withdrawn) The isolated nucleic acid of claim 25 further comprising genetic elements useful for construction of viral vectors.

28. (Cancelled)